Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Sell
15
MDRX Quote, Financials, Valuation and Earnings
Last price:
$4.25
Seasonality move
:
-1.72%
Day range:
$4.25 - $4.45
52-week range:
$4.00 - $11.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.89x
P/B ratio:
0.45x
Volume:
493.8K
Avg. volume:
232.5K
1-year change:
-45.51%
Market cap:
$460.1M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingVeradigm has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, Veradigm has an estimated upside of 135.29% from its current price of $4.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $4.25.
Fair Value
-
According to the consensus of 3 analysts, Veradigm has 135.29% upside to fair value with a price target of $10.00 per share.
MDRX vs. S&P 500
-
Over the past 5 trading days, Veradigm has overperformed the S&P 500 by 2.52% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Veradigm does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Veradigm revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Veradigm reported revenues of --.
Earnings Growth
-
Veradigm has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Veradigm reported earnings per share of --.
Enterprise value:
213.9M
EV / Invested capital:
--
Price / LTM sales:
0.89x
EV / EBIT:
1.55x
EV / Revenue:
0.36x
PEG ratio (5yr expected):
--
EV / Free cash flow:
2.57x
Price / Operating cash flow:
6.31x
Enterprise value / EBITDA:
3.66x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2021-12-31 | 2022-12-31 | |
| Income Statement | ||||||
| Revenue | $1.5B | $577.4M | $588M | $157.9M | $142.5M | |
| Gross Profit | $565.7M | $282.4M | $308.4M | $81.5M | $72M | |
| Operating Income | -$55.9M | $77.3M | -$19.6M | $33.7M | -$45.8M | |
| EBITDA | $77.1M | $243.4M | $58.4M | $121.5M | -$12.6M | |
| Diluted EPS | $4.39 | $1.01 | -$0.81 | $0.68 | -$0.54 | |
| Period Ending | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $859M | $841.3M | $1.2B | $649.2M | $679.6M | |
| Total Assets | $3.2B | $3.2B | $2.9B | $2.3B | $1.5B | |
| Current Liabilities | $797.7M | $1.2B | $934.8M | $488.4M | $230.3M | |
| Total Liabilities | $1.6B | $1.9B | $1.3B | $950.6M | $487.2M | |
| Total Equity | $1.6B | $1.3B | $1.7B | $1.4B | $1B | |
| Total Debt | $667.6M | $915.5M | $167.6M | $350.1M | $200.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2021-12-31 | 2022-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$106.7M | -$76.6M | $115.6M | $63.9M | $19.8M | |
| Cash From Investing | $1.6B | -$12.7M | $585.1M | $42.2M | -$18.6M | |
| Cash From Financing | -$1.1B | -$258.9M | -$444.9M | -$133.5M | -$57.5M | |
| Free Cash Flow | -$211.7M | -$118M | $83.3M | $50.1M | $15.6M | |
MDRX
Sector
Market Cap
$460.1M
$37M
Price % of 52-Week High
36.02%
43.14%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.03%
1-Year Price Total Return
-45.51%
-43.58%
Beta (5-Year)
0.627
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.26
200-day SMA
Sell
Level
$8.69
Bollinger Bands (100)
Sell
Level
5.37 - 10.29
Chaikin Money Flow
Buy
Level
202.4M
20-day SMA
Sell
Level
$4.75
Relative Strength Index (RSI14)
Sell
Level
34.51
ADX Line
Sell
Level
23.43
Williams %R
Buy
Level
-85.119
50-day SMA
Sell
Level
$5.62
MACD (12, 26)
Sell
Level
-0.42
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-93.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Veradigm Inc is a healthcare technology company that drives value through its various combinations of platforms, data, expertise, connectivity, and scale. The company delivers a combination of point-of-care clinical and financial solutions. The Veradigm Network features a dynamic community of solutions and partners providing insights, technology, and data-driven solutions for the healthcare provider, payer, and Life Science markets.
Stock Forecast FAQ
In the current month, MDRX has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The MDRX average analyst price target in the past 3 months is $10.00.
-
Where Will Veradigm Stock Be In 1 Year?
According to analysts, the consensus estimate is that Veradigm share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Veradigm?
Analysts are divided on their view about Veradigm share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Veradigm is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Veradigm's Price Target?
The price target for Veradigm over the next 1-year time period is forecast to be $10.00 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is MDRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Veradigm is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MDRX?
You can purchase shares of Veradigm via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Veradigm shares.
-
What Is The Veradigm Share Price Today?
Veradigm was last trading at $4.25 per share. This represents the most recent stock quote for Veradigm. Yesterday, Veradigm closed at $4.25 per share.
-
How To Buy Veradigm Stock Online?
In order to purchase Veradigm stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
100
DLICY alert for Apr 2
Dai-ichi Life Holdings [DLICY] is up 100.91% over the past day.
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Sell
15
PCVX alert for Apr 2
Vaxcyte [PCVX] is down 14.62% over the past day.
